Background
Methods
Study design
Study population
Swiss healthcare system and regulation for opioid prescription
Definitions
Statistical methods
Results
NSAID/Coxibs | Paracetamol | Metamizole | Weak Opioids | Strong Opioids | |
---|---|---|---|---|---|
Number of claims: n total | 2'156'620 | 4'746'942 | 931'129 | 1'322'272 | 807'835 |
Number of persons: n | 693'928 | 1'098'925 | 292'403 | 268'143 | 121'455 |
Morphine equivalent: median (IQR)a
| - | - | - | 180 (531) | 300 (2680.1) |
Male: n (%) | 293'011 (42.2) | 484'176 (44.1) | 120'609 (41.2) | 111'888 (41.7) | 50'329 (41.4) |
Female: n (%) | 400'917 (57.8) | 614'749 (55.9) | 171'794 (58.8) | 156'255 (58.3) | 71'126 (58.6) |
Age: median (IQR) | 39 (41) | 38 (45) | 54 (35) | 57 (31) | 64 (30) |
Age male: median (IQR) | 36 (43) | 36 (47) | 52 (33) | 55 (29) | 61 (29) |
Age female: median (IQR) | 41 (40) | 40 (43) | 55 (37) | 59 (32) | 67 (31) |
German partb: n persons (%) | 464'237 (66.9%) | 766'415 (69.7%) | 257'420 (88.0%) | 195'149 (72.8%) | 101'664 (83.7%) |
French partb: n persons (%) | 195'934 (28.2%) | 259'895 (23.6%) | 22'835 (7.8%) | 57'929 (21.6%) | 15'642 (12.9%) |
Italian partb: n persons (%) | 33'757 (4.9%) | 72'615 (6.6%) | 12'148 (4.2%) | 15'065 (5.6%) | 4'149 (3.4%) |
German partb: n claims (%) | 1'416'848 (65.7%) | 3'059'364 (64.4%) | 845'951 (90.9%) | 962'477 (72.8%) | 671'079 (83.1%) |
French partb: n claims (%) | 637'028 (29.5%) | 1'320'874 (27.8%) | 54'124 (5.8%) | 286'570 (21.7%) | 109'364 (13.5%) |
Italian partb: n claims (%) | 102'744 (4.8%) | 366'704 (7.7%) | 31'054 (3.3%) | 73'225 (5.5%) | 27'392 (3.4%) |
Change in claims for non-opioid pain medications
Non-opioids | 2006 | 2013 | % Diff 06-13 |
Number of personsa: | 455'845 | 501'996 | 10 |
Age: median (IQR) | 47 (41) | 48 (41) | |
Female: n (%) | 265'135 (58.2) | 288'289 (57.4) | |
Number of claims: n | 1'342'454 | 1'657'420 | 23 |
Number of claims / person | 2.94 | 3.3 | 12 |
Paracetamol: number of claims | 512'762 | 639'716 | 25 |
Metamizole: number of claims | 55'000 | 185'168 | 237 |
NSAIDb: number of claims | 174'293 | 329'075 | 89 |
Coxibs: number of claims | 22'809 | 39'743 | 74 |
Paracematol: claims / 100'000 | 40'211 | 53'062 | 32 |
Metamizole: claims / 100'000 | 4'018 | 13'729 | 242 |
NSAID + Coxibs claims / 100'000 | 15'634 | 31'995 | 105 |
NSAID claims / 100'000 | 1'049'968 | 2'354'922 | 124 |
Coxibs claims / 100'000 | 123'981 | 249'306 | 101 |
Ibuprofen: claims / 100'000 | 235 | 395 | 68 |
Paracetamol: 1000 mg / 100'000 | 1'116'931 | 2'717'129 | 143 |
Metamizole: 1000 mg / 100'000 | 61'074 | 501'196 | 721 |
Weak opioids | 2006 | 2013 | % Diff 06-13 |
Number of personsa
| 53'786 | 55'604 | 3 |
Age: median (IQR) | 61 (29) | 62 (30) | |
Female: n (%) | 33'172 (62) | 33'629 (60) | |
Number of claims#: n | 160'517 | 167'278 | 4 |
Number of claims / person | 2.98 | 3.01 | 1 |
Number of claims / 100'000 | 11'957 | 13'348 | 13 |
Total MED in mg | 50'339 | 57'782 | 15 |
Total MED in mg/Person | 936 | 1'039 | 11 |
Total MED in 1000 mg/ 100'000 | 3'768 | 4'655 | 24 |
Tramadol in MED 1000 mg/ 100'000 | 3'046 | 3'750 | 23 |
Codeine MED in 1000 mg/ 100'000 | 722 | 587 | −19 |
Tapentadol MED in 1000 mg / 100'000 | - | 317 | - |
Strong opioids | 2006 | 2013 | % Diff 06-13 |
Number of personsa
| 16'744 | 28'509 | 70 |
Age: median (IQR) | 66 (27) | 69 (29) | |
Female: n (%) | 10'297 (62) | 17'570 (62) | |
Number of claims: n | 64'839 | 137'458 | 112 |
Number of claims / person | 3.87 | 4.82 | 25 |
Number of claims / 100'000 | 4'716 | 10'419 | 121 |
Total MED 1000 mg | 146'151 | 294'320 | 101 |
Total MED in mg/Person | 8'729 | 10'324 | 18 |
Total treatment days | 1'199 | 2'274 | 90 |
Total treatment days/ person | 72 | 80 | 11 |
Total MED in 1000 mg/ 100'000 | 11'011 | 23'854 | 117 |
Total treatment days / 100'000 | 89'903 | 180'371 | 101 |
Total MED / treatment day | 121.9 | 129.4 | 6 |
Morphine: MED 1000 mg / 100'000 | 2'875 | 4'648 | 62 |
Oxycodone and comb: MED 1000 mg / 100'000 | 1'237 | 5'110 | 313 |
Fentanyl: MED 1000 mg / 100'000 | 3'588 | 6'851 | 91 |
Pethidine: MED 1000 mg / 100'000 | 33 | 39 | 18 |
Hydromorphone: MED 1000 mg / 100'000 | 548 | 730 | 33 |
Methadone: MED 1000 mg / 100'000 | 28 | 424 | 1414 |
Buprenorphine: MED 1000 mg / 100'000 | 2'699 | 6'049 | 124 |
Nalbuphine: MED 1000 mg / 100'000 | 2 | 2 | 0 |
Morphine: treatment days / 100'000 | 28'988 | 46'856 | 62 |
Oxycodone: treatment days / 100'000 | 10'994 | 45'422 | 313 |
Fentanyl: treatment days / 100'000 | 29'941 | 57'953 | 94 |
Pethidine: treatment days / 100'000 | 411 | 491 | 19 |
Hydromorphone: treatment days / 100'000 | 3'657 | 4'988 | 36 |
Methadone: treatment days / 100'000 | 373 | 5'645 | 1413 |
Buprenorphine: treatment days / 100'000 | 15'509 | 18'985 | 22 |
Nalbuphine: treatment days / 100'000 | 31 | 30 | −3 |
Oral long acting: MED 1000 mg / 100'000 | 4'409 | 9'761 | 121 |
Oral short acting: MED 1000 mg / 100'000 | 142 | 865 | 509 |
Parenteral: MED 1000 mg / 100'000 | 168 | 328 | 95 |
Rectal: MED 1000 mg / 100'000 | 5 | 9 | 80 |
Sublingual: MED 1000 mg / 100'000 | 1'243 | 4'986 | 301 |
Transdermal: MED 1000 mg / 100'000 | 5'045 | 7'905 | 57 |